Anika Therapeutics Gross Margin 2006-2021 | ANIK

Current and historical gross margin for Anika Therapeutics (ANIK) over the last 10 years. The current gross profit margin for Anika Therapeutics as of September 30, 2021 is %.
Anika Therapeutics Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2021-09-30 $0.15B $0.08B 56.55%
2021-06-30 $0.14B $0.08B 55.47%
2021-03-31 $0.13B $0.07B 53.08%
2020-12-31 $0.13B $0.07B 52.67%
2020-09-30 $0.13B $0.07B 57.03%
2020-06-30 $0.13B $0.08B 63.49%
2020-03-31 $0.13B $0.09B 72.00%
2019-12-31 $0.12B $0.09B 74.78%
2019-09-30 $0.11B $0.09B 75.89%
2019-06-30 $0.11B $0.08B 73.39%
2019-03-31 $0.11B $0.08B 70.91%
2018-12-31 $0.11B $0.07B 69.81%
2018-09-30 $0.11B $0.08B 69.44%
2018-06-30 $0.11B $0.08B 71.30%
2018-03-31 $0.11B $0.08B 74.55%
2017-12-31 $0.11B $0.09B 76.79%
2017-09-30 $0.11B $0.09B 76.79%
2017-06-30 $0.11B $0.09B 77.48%
2017-03-31 $0.11B $0.08B 76.19%
2016-12-31 $0.10B $0.08B 76.92%
2016-09-30 $0.11B $0.08B 79.25%
2016-06-30 $0.10B $0.08B 78.85%
2016-03-31 $0.10B $0.08B 79.00%
2015-12-31 $0.09B $0.07B 77.66%
2015-09-30 $0.09B $0.07B 76.74%
2015-06-30 $0.08B $0.06B 75.00%
2015-03-31 $0.09B $0.07B 75.86%
2014-12-31 $0.11B $0.09B 80.95%
2014-09-30 $0.10B $0.08B 79.61%
2014-06-30 $0.10B $0.08B 78.79%
2014-03-31 $0.09B $0.07B 76.60%
2013-12-31 $0.08B $0.05B 69.33%
2013-09-30 $0.08B $0.05B 67.53%
2013-06-30 $0.07B $0.05B 64.86%
2013-03-31 $0.07B $0.05B 61.64%
2012-12-31 $0.07B $0.04B 59.72%
2012-09-30 $0.07B $0.04B 58.21%
2012-06-30 $0.07B $0.04B 60.00%
2012-03-31 $0.07B $0.04B 59.09%
2011-12-31 $0.06B $0.04B 57.81%
2011-09-30 $0.06B $0.03B 55.74%
2011-06-30 $0.06B $0.03B 54.39%
2011-03-31 $0.06B $0.03B 56.36%
2010-12-31 $0.06B $0.03B 58.18%
2010-09-30 $0.05B $0.03B 60.78%
2010-06-30 $0.05B $0.03B 62.50%
2010-03-31 $0.04B $0.03B 61.36%
2009-12-31 $0.04B $0.03B 63.41%
2009-09-30 $0.04B $0.03B 64.10%
2009-06-30 $0.04B $0.02B 64.86%
2009-03-31 $0.04B $0.02B 63.89%
2008-12-31 $0.04B $0.02B 61.11%
2008-09-30 $0.04B $0.02B 59.46%
2008-06-30 $0.04B $0.02B 58.33%
2008-03-31 $0.03B $0.02B 58.82%
2007-12-31 $0.03B $0.02B 61.29%
2007-09-30 $0.03B $0.02B 59.26%
2007-06-30 $0.03B $0.02B 60.00%
2007-03-31 $0.03B $0.02B 61.54%
2006-12-31 $0.03B $0.02B 59.26%
2006-09-30 $0.03B $0.02B 61.54%
2006-06-30 $0.03B $0.02B 60.00%
2006-03-31 $0.03B $0.02B 62.07%
2005-12-31 $0.03B $0.02B 62.07%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.572B $0.130B
Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09